Paragon 28 Adds Second Mobile Medical Education Lab, Significantly Expanding Hugely Successful Training Program for Foot and Ankle Surgeons

ENGLEWOOD, CO, November 13, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile laboratory training program, making it even easier for the company to facilitate on-site training and education of surgeons. Paragon 28’s new mobile laboratory is housed in a 40-foot tractor-trailer with a state-of-the-art cadaver training facility with 5 stations and space for up to 25 surgeons. The mobile laboratory will host more than 70 training sessions in approximately 65 U.S. cities in the fourth quarter of 2023. The mobile laboratory program launched in July 2022 and has been an incredible success for Paragon 28, allowing the company to efficiently train more than 350 surgeons.

“We are very excited to add a second laboratory to our mobile education program and increase our ability to bring education directly to surgeons. The mobile laboratory program has enabled Paragon 28 to find the most effective location for medical education to support our growing product portfolio and surgeon customers,” said Albert DaCosta, CEO and co-founder of Paragon 28. “The mobile laboratory program has proven to be an effective and versatile option to showcase P28’s broad and innovative product portfolio, which includes new solutions in the growing forefoot, HAV and rearfoot market segments.”

For more information about the Paragon 28 Surgeon Mobile Lab, visit the following site: Paragon 28 Mobile Lab

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28 is a leading medical device company focused exclusively on the foot and ankle orthopedic market and committed to improving the lives of patients. Since its inception, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and devices covering a wide range of foot and ankle conditions, including fracture fixation, hallux valgus (bunions), hammer toe, ankle, progressive collapsible foot deformity (PCFD) or flat foot, Charcot foot and orthobiology. The company designs products with both the patient and surgeon in mind, with the goals of improving outcomes, reducing recurrences of disease and complications, and making procedures simpler, more consistent and reproducible.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates and assumptions, which speak only as of the date on which they are made, and are subject to risks and uncertainties, some of which we are not currently aware of. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at or at which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Paragon 28’s business generally, see the current and future reports from Paragon 28 filed with the Securities and Exchange Commission. Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements . except as required by law.

Contacts

Contact person for investors

Matthew Brinckman
Senior Vice President, Strategy and Investor Relations
Phone: (720) 912-1332
mbrinckman@paragon28.com

Image: Business Wire